SUZHOU, China and ROCKVILLE, Md., May 10, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that latest clinical data of the company’s drug candidates, including the MDM2-p53 inhibitor APG-115, novel Bcl-2/Bcl-xL dual inhibitor APG-1252, and IAP Read More ›

SUZHOU, China, and ROCKVILLE, Md., May 7, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted HQP1351, the Company’s core drug candidate, a Fast Track Designation (FTD) Read More ›

SUZHOU, China, and ROCKVILLE, Md., May 4, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (US FDA) has granted HQP1351, the Company’s core drug candidate, an Orphan Drug Read More ›

SUZHOU, China, and ROCKVILLE, MD, April 7, 2020, Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has received approval from the Center for Drug Evaluation of the China National Medical Products Administration for the Phase Ib/II Read More ›

SUZHOU, China, and ROCKVILLE, MD, March 29, 2020, Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released its annual results for the year ended December 31, 2019. During the reported period, Ascentage Pharma further increased its investments in innovation, and Read More ›

SUZHOU, China, and ROCKVILLE, MD, March 23, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the global Phase Ib/II clinical study of APG-2575, a Bcl-2 selective inhibitor, as a single agent or in combination for Read More ›

SUZHOU, China, and ROCKVILLE, MD, March 9, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that two clinical studies of APG-2575, a novel Bcl-2 selective inhibitor being developed by Ascentage Pharma, have recently received clearances from Read More ›

SUZHOU, China and ROCKVILLE, MD., February 24, 2020 — Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has received approval from Center of Drug Evaluation (CDE), China NMPA, for the Phase Ib/II clinical trial of APG-1387, Read More ›

SUZHOU, China and ROCKVILLE, Md., Dec. 10, 2019 /PRNewswire/ – Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the updated results from the Phase I study of the company’s novel investigational drug HQP1351 were reported in an oral presentation at the 61st American Society of Read More ›

SUZHOU, China and ROCKVILLE, Md., Nov. 20, 2019 /PRNewswire/ — Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies, announced that the groundbreaking ceremony for the Company’s global headquarters, R&D center, and manufacturing facility took place today at the Suzhou Industrial Park (SIP). The ceremony marks another milestone in Ascentage Pharma’s path of Read More ›